Dr Dave Tudor has been appointed managing director of the Medicines Manufacturing Innovation Centre by the Centre for Process Innovation (CPI).
Tudor will be responsible for delivering the business strategy and said he will help the centre achieve its “ultimate goal” of lowering the cost of drugs, making healthcare more affordable for providers and patients.
After completing a PhD in chemistry from Glasgow University, Tudor joined SmithKline Beecham in 1992 and moved to GSK in 1997. He has held various management and leadership positions throughout his 27 years working in the pharmaceutical industry.
The centre is a facility offering ‘transformative solutions’ in small molecule and fine chemical manufacturing and is a collaboration between CPI, the University of Strathclyde, GSK and AstraZeneca.
It is being supported by a £13m investment from UK Research and Innovation, through the Industrial Strategy Challenge Fund (ISCF), along with £15m from Scottish Enterprise and £7 million from both GSK and AstraZeneca.
Commenting on his appointment, Tudor said: “I’m excited to begin my role as Managing Director of the Centre and to have the chance to create a transformative strategy for life science in the UK.
“My aim is to connect the industry and bring partners together to work in a non-competitive way. What really motivates me is the idea that we can avoid waste, reduce costs and make these medicines more accessible and more affordable. Anything that can be done to transform the product and make it cheaper has got to be a good thing.”
Andy Jones, ISCF Medicines Manufacturing challenge director, added: “I’m looking forward to working closely with Dave Tudor and his whole team to drive this crucial phase of turning the Medicines Manufacturing Innovation Centre from plans into reality.
“The Centre is a vital new facility for the whole of the UK, both in terms of saving more lives and creating even better conditions for Life Sciences companies to thrive and grow in a fiercely competitive global market.”